No connection

Search Results

ADMA vs TLX

ADMA
ADMA Biologics, Inc.
BEARISH
Price
$15.15
Market Cap
$3.61B
Sector
Healthcare
AI Confidence
85%
TLX
Telix Pharmaceuticals Limited
NEUTRAL
Price
$10.73
Market Cap
$3.64B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
ADMA
25.25
TLX
--
Forward P/E
ADMA
10.98
TLX
43.42
P/B Ratio
ADMA
7.55
TLX
8.75
P/S Ratio
ADMA
7.07
TLX
4.52
EV/EBITDA
ADMA
18.04
TLX
122.01

Profitability

Gross Margin
ADMA
57.38%
TLX
47.5%
Operating Margin
ADMA
45.09%
TLX
1.94%
Profit Margin
ADMA
28.8%
TLX
-0.89%
ROE
ADMA
35.56%
TLX
-1.85%
ROA
ADMA
21.5%
TLX
1.15%

Growth

Revenue Growth
ADMA
18.4%
TLX
49.3%
Earnings Growth
ADMA
-52.8%
TLX
--

Financial Health

Debt/Equity
ADMA
0.17
TLX
1.12
Current Ratio
ADMA
6.71
TLX
1.43
Quick Ratio
ADMA
3.54
TLX
1.21

Dividends

Dividend Yield
ADMA
--
TLX
--
Payout Ratio
ADMA
0.0%
TLX
0.0%

AI Verdict

ADMA BEARISH

ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.

Strengths
Exceptional gross and operating margins (57.38% and 45.09%) indicate strong pricing power and cost control
High ROE of 35.56% demonstrates efficient use of equity capital
Low debt/equity ratio of 0.17 and high current ratio of 6.71 signal strong financial stability
Risks
Piotroski F-Score of 3/9 indicates weak financial health and high distress risk
Earnings have declined sharply by 52.8% YoY, contradicting revenue growth of 18.4%
Insider selling of $1.58M in six months, including multiple large sales by the CEO, signals lack of confidence
TLX NEUTRAL

TLX presents a stark contrast between fundamental health and growth potential. The deterministic baseline is severely compromised, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company exhibits strong top-line revenue growth of 49.3% and maintains a 'Strong Buy' analyst consensus with a target price of $21.64, the negative net profit margin and bearish technical trend suggest significant near-term risk. The investment thesis relies entirely on future growth scaling rather than current financial stability.

Strengths
Strong YoY revenue growth of 49.30%
Healthy gross margins at 47.50%
Strong analyst consensus (Strong Buy) with significant upside to target price
Risks
Critical financial health deterioration (Piotroski F-Score 1/9)
Negative net profit margin (-0.89%) and negative ROE (-1.86%)
High valuation premium with a Price/Book ratio of 8.75

Compare Another Pair

ADMA vs TLX: Head-to-Head Comparison

This page compares ADMA Biologics, Inc. (ADMA) and Telix Pharmaceuticals Limited (TLX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile